INTRODUCTION
It is well established that specialists often adopt new medical technologies earlier than generalists [1] [2] [3] [4] [5] , and that White patients are more likely than racial and ethnic minority patients to receive many devices and prescription drugs, including hip and knee replacements, vaccinations, and medicines for HIV infection or depression [6] [7] [8] . Overuse by White patients may explain some of these differences (see, for example, 9, 10 ); however, studies suggest that minority patients receive fewer clinically important, necessary services than White patients [9] [10] [11] [12] . Little is known about the role that specialists or generalists may play in reducing racial and ethnic disparities in the use of medical technologies.
Cervical cancer screening tests are widely used technologies that present a rich context for exploring patterns of use across patient and provider subgroups. Although most women in the United States receive Pap tests more frequently than recommended by clinical practice guidelines 13 , underuse of cervical cancer screening tests is also common, particularly among those with lower incomes and Medicaid coverage 14, 15 . Screening intervals are wider for Black and Hispanic women than for White women 16, 17 , and narrower for women who see gynecologists rather than primary care providers 18 .
Until 2000, cervical cancer screening was conducted solely using Pap tests, which detect cervical abnormalities before they progress, allowing for early treatment. In 2000, the Food and Drug Administration (FDA) approved Digene Corporation's (now QIAGEN, Valencia, CA) human papillomavirus (HPV) DNA test for follow-up of equivocal Pap test results, referred to as atypical squamous cells of uncertain significance (ASC-US). In March 2003, the FDA approved a second indicated use, HPV DNA testing for primary screening in women over age 30, in conjunction with the Pap test 19 . Primary screening in women under age 30 is not recommended, as there is a high prevalence of spontaneously resolving transient HPV infections among younger women 20 .
Between April 2002 and February 2004, five sets of cervical cancer screening guidelines were released by professional associations and consensus groups [20] [21] [22] [23] [24] . With the exception of guidelines from the US Preventive Services Task Force, which cited insufficient evidence to recommend for or against routine screening for HPV infection 21 , the guidelines generally agreed that HPV DNA testing is one option for following up ASC-US Pap test results, and for use in combination with a Pap test in women age 30 and over (Appendix) [20] [21] [22] [23] [24] . 27 . I measured the absolute uptake of HPV DNA tests over time and after the introduction of multiple sets of clinical guidelines; calculated the degree to which the technology was used in a manner consistent with those guidelines; and assessed whether uptake of HPV DNA tests occurred at differential rates for Medicaid beneficiaries of different races and ethnicities, and for physicians of different specialties. I hypothesized that clinical guidelines would be associated with significant increases in HPV DNA test use, that White beneficiaries would be more likely to receive the tests than Black or Hispanic beneficiaries, and that obstetricians/ gynecologists would be more likely to administer the tests than generalists.
METHODS

Data
I used linked enrollment and claims files from the Florida Medicaid program for the period July 2001 through June 2006, analyzing data for female patients between the ages of 21 and 64. To ensure that the data included a complete claims history for each woman, the study included only those eligible for Medicaid through Aid to Families with Dependent Children or Temporary Assistance for Needy Families (AFDC/ TANF), family planning, or pregnancy. To allow for adequate assessments of cervical screening and follow-up, only those participants enrolled in Medicaid for at least 12 consecutive months were included. Women who had a hysterectomy during the study period were excluded, as guidelines do not recommend that they receive cervical cancer screening 19 ;
however, I could not identify and exclude women with a previous hysterectomy. 795 .01. A small number of HPV DNA tests in the sample could not be classified into these categories; these tests were deemed "appropriate" to allow for physician discretion to administer tests for non-guideline uses.
Outcome Variables
The diagnostic code for ASC-US was first introduced in October 2002 28 , and frequent use of the code did not appear in Florida Medicaid claims until October 2004. Since ASC-US diagnosis codes were impossible to use in the first portion of the study period, and likely underused until late 2004, some HPV DNA tests used for ASC-US triage are missed by relying upon the ASC-US diagnosis code alone. To identify tests used for ASC-US triage that were not claimed using the diagnosis code, I estimated which HPV DNA test claims were associated with HPV positive patients, and assumed that an equal number of patients were HPV-negative, since clinical trials have found that approximately half of those with ASC-US Pap test results are HPV-positive 29 . I identified HPV positive patients as those who received an HPV DNA test and then had a claim with an HPV-positive diagnosis (ICD-9 code 795.05), or a procedure code for a colposcopy (Appendix), the recommended follow-up for HPV-positive diagnosis, within 3 months. Clinical practice guidelines recommend the HPV DNA test as an option, rather than as a preferred alternative, so failure to administer an HPV DNA test for a recommended purpose was not considered in the analysis of appropriate use. Appropriateness was only assessed for HPV DNA tests that were conducted, not for all situations in which they could have been conducted appropriately.
Explanatory Variables
The independent variables in the study included patient age, race/ethnicity, Medicaid district, and total months of enrollment, as provided by the annual Medicaid enrollment files; provider specialty, according to whether the provider who submitted the claim for the most recent clinical visit was a primary care provider (including internal medicine specialists, family and general practice physicians, and nurse practi-tioners), obstetrician/gynecologist, pathologist, or other specialty; and pathology lab volume, defined as "high" for those labs submitting more than 20,000 test claims in the dataset.
The passage of time was modeled using a variable ranging in value from 1 to 60, representing the months of the study period, where 1 indicated July 2001 and 60 indicated June 2006. The effects of the FDA approval and clinical guideline releases were modeled in several ways. The results of these models were generally similar; therefore, results are reported using the most readily interpretable approach: simple dummy variables for each of the events, assigned to zero for the months before each event, and to one beginning the month after the event through the end of the study period.
Statistical Analyses
I calculated the number of HPV DNA tests per 100,000 Medicaid beneficiaries, and the clinical indications and appropriateness of these test applications, using the definitions of appropriateness defined above, for each month of the data.
To account for correlation between repeated observations of the same patients over time, associations between predictors and HPV DNA test use were evaluated using generalized estimating equations (GEE) with a logit link. An exchangeable correlation matrix structure was assumed 30 . Robust standard error estimates were used to account for patient clustering within providers 31 . Models predicting the likelihood of receiving an HPV DNA test were conditional on having received any cervical screening test; models predicting the likelihood of receiving an "appropriate" HPV DNA test were conditional on having received an HPV DNA test. I examined differential uptake of the test across patient and provider groups by conducting tests of the interactions among patient race/ethnicity, provider specialty, and the time trend variable; significant interaction terms were retained in the final model. To ensure consistency in the definition of appropriate use, the time frame for the appropriate use analysis was limited to March 2003, the date of FDA approval of HPV DNA tests for primary screening, through the end of the study period, June 2006.
Statistical analyses were conducted with SAS version 9.1.3 (SAS Institute Inc, Cary, NC). Statistical significance was set at the 0.05 level, and all tests were two-sided.
RESULTS
The mean age of the Medicaid beneficiaries across the study period was 30 years; 40.4% of the women were White, 34.1% were Black, and 22.9% were Hispanic (Table 1) . Forty percent received one or more Pap tests and/or HPV DNA tests during the study period, for a total of 310,427 cervical cancer screening tests. Overall, the proportion of beneficiaries receiving one or more HPV DNA tests was 2.9%, for a total of 13,550 HPV DNA tests. Of all HPV DNA tests for which provider specialty could be identified, 62.6% were performed by obstetricians/gynecologists, and 25.2% were performed by primary care providers.
HPV DNA test use increased steadily over the study period, rising from 0.6% of all cervical tests in July 2001 to 9.0% in Table 2) . Some subsequent guideline introductions were significantly associated with more modest increases.
Interactions between the release of clinical guidelines by professional associations and clinical behavior by members of those associations were not significant in any of our models. For example, guidelines from the American College of Obstetricians and Gynecologists had no more effect on OB/GYNs than on other provider specialties.
Black and Hispanic women were less likely than White women to receive HPV DNA tests throughout much of the study period (AOR = 0.66, p < 0.0001 and AOR = 0.49, p < 0.0001, respectively), but HPV DNA test use grew more rapidly among minority women than among White women. By the end of the study period, the monthly rate of HPV DNA test use for Black and Hispanic women exceeded that for White women (Fig. 2) .
Across all patient race and ethnic groups, specialists were significantly more likely than generalist providers to administer HPV DNA tests; the predicted probability of a patient of any age or race/ethnicity receiving an HPV DNA test was 0.06 for those seeing an obstetrician/gynecologist and 0.03 for those seeing a primary care provider (Fig. 2) . HPV DNA test use did not increase more rapidly among obstetricians/gynecologists than among primary care providers. However, obstetricians/ gynecologists had a higher predicted probability of administering HPV DNA tests to their Black and Hispanic patients than to their White patients (0.07 and 0.06, respectively, vs. 0.05).
In multivariate models predicting appropriate HPV DNA test use for primary screening, clinical guideline releases were not consistently associated with appropriate use, and the proportion of HPV DNA tests administered appropriately did not differ across patients of different races/ethnicities or providers of different specialties (Table 3) .
DISCUSSION
In this large study of Florida Medicaid beneficiaries, there were significant increases in both overall and clinically appropriate use of HPV DNA tests from July 2001 to June 2006. Many factors may have contributed to rising uptake, including marketing to health care providers, prominent journal articles, or lay press coverage. In addition, development and release of multiple sets of clinical guidelines may have helped to sustain adoption of HPV DNA tests in clinical practice, as uptake of the test increased greatly after the introduction of the first set of guidelines incorporating HPV DNA testing and increased further after some subsequent guideline releases.
Adoption of the HPV DNA test differed significantly across provider specialty and by patient race/ethnicity. Although no specialized training is needed to conduct HPV DNA tests, obstetricians/gynecologists were more likely than primary care providers to use HPV DNA tests overall. This finding is in keeping with previous research on specialists' differential adoption of diagnostic tests and treatments, including liquidbased cervical cancer screening tests 5 , antibiotics for H. pylori , and COX-2 inhibitors for arthritic and musculoskeletal pain 2 .
Possible explanations for earlier adoption by specialists include a larger caseload of patients for whom the test is indicated; manufacturer marketing efforts that preferentially target specialists; or attendance at professional meetings at which guidelines are formulated and discussed several months or years before their formal publication. In addition, the USPSTF's statement that there was insufficient evidence to recommend use of the HPV DNA test may have disinclined primary care providers to use the test for its FDA-approved indications.
Although Black and Hispanic women receiving cervical screening were initially less likely to receive HPV DNA tests, over time their growth in usage met and surpassed that of White women. This difference in adoption rates was not explained by differences in patient age or Pap test results across racial/ethnic groups. However, HPV DNA test administration by obstetricians/gynecologists was higher among Black and Hispanic patients than among White patients. The [32] [33] [34] [35] . Clinical practice guidelines have the potential to promote appropriate use 36 . However, in this study, guidelines were not associated with increases in appropriate HPV DNA test use. These findings are consistent with evidence that adherence to guidelines is often poor 37 . Barriers to guideline adherence among physicians include lack of awareness, unfamiliarity or disagreement with guidelines; lack of motivation or self-efficacy to change existing practice; resistance from patients; and lack of time, resources, or financial incentives 38 . Various strategies, such as reminders, educational outreach, information technology systems, and financial incentives, have been shown to overcome these barriers [39] [40] [41] .
Limitations
This study has several limitations. First, screening tests may have been missed if claims were not submitted. However, regular cervical screening, including unrestricted use of HPV DNA testing, was a reimbursed service of Florida Medicaid throughout the study period, so it seems unlikely that a substantial number of these services were performed with no associated claims filed. 
